How Cannabis-Based Therapeutics Could Help Fight COVID Inflammation Liz Scherer Medscape.com, November 03, 2020 Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Plagued by false starts, a few dashed hopes, but with perhaps a glimmer of light on the horizon, the race to find an effective treatment for COVID-19 continues. At last count, more than 300 treatments and 200 vaccines were in preclinical or clinical development (not to mention the numerous existing agents that are being evaluated for repurposing). There is also a renewed interest in cannabinoid therapeutics — in particular, the nonpsychoactive agent cannabidiol (CBD) and the prospect of [...]
Lire la suiteThe EU CBD CONSUMER REPORT SERIES : Segmentation & Archetypes Executive Summary, Volume II New Frontier Data 2019-2020, European CBD Survey, 7 pp. As the active ingredient cannabidiol (CBD) from cannabis has undergone an explosive growth in popularity, consumers in the European Union (EU) are increasingly being exposed to information and products—and trying to understand the cannabinoid’s potential and how it might best fit into their lives. As of February 2020, within the EU’s 27 member states, its 445 million citizens find increasing opportunities to participate in the burgeoning CBD market, and brands will play a critical role in defining their experiences. Having already [...]
Lire la suiteLutte contre les stupéfiants : la stigmatisation doit cesser ! Les récentes prises de parole du Ministre de l’Intérieur quant à sa stratégie de lutte contre les usages de stupéfiants révèlent un mépris envers les usagers-ères et une incohérence dans les politiques menées. Nous, Nous, associations travaillant auprès des usagers, magistrats, avocats, policiers, usagers, ne pouvons tolérer ces propos et les directions prises qui stigmatisent et précarisent encore davantage des populations déjà vulnérabilisées par 50 ans de politiques répressives. Afin d’assurer le service après-vente de la généralisation de l’Amende Forfaitaire Délictuelle, le ministre de l’intérieur multiplie les prises de parole, bombant le [...]
Lire la suiteNeural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man : A Critical Review of Neuroimaging Studies Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Jose A. Crippa and Philip K. McGuire Current Pharmaceutical Design, 2012, 18, 5045-5054 Abstract Pharmacological challenge in conjunction with neuroimaging techniques has been employed for over two decades now to understand the neural basis of the cognitive, emotional and symptomatic effects of the main ingredients of cannabis, the most widely used illicit drug in the world. This selective critical review focuses on the human neuroimaging studies investigating the effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), the two main cannabinoids [...]
Lire la suiteCannabidiol for the treatment of cannabis use disorder : a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial Tom P Freeman, Chandni Hindocha, Gianluca Baio, Natacha D C Shaban, Emily M Thomas, Danica Astbury, Abigail M Freeman, Rachel Lees, Sam Craft, Paul D Morrison, Michael A P Bloomfield, Dominic O'Ryan, Jane Kinghorn, Celia J A Morgan, Ali Mofeez, H Valerie Curran The Lancet Psychiatry, 2020, doi : 10.1016/S2215-0366(20)30290-X Abstract Background : A substantial and unmet clinical need exists for pharmacological treatment of cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which doses might be efficacious or safe. Therefore, we aimed to identify efficacious doses and eliminate inefficacious doses in a phase 2a trial using [...]
Lire la suiteCytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells : Different Mechanisms of THC, CBD, and CB83 Daniela Cerretani, Giulia Collodel, Antonella Brizzi, Anna Ida Fiaschi, Andrea Menchiari, Elena Moretti, Laura Moltoni, Lucia Micheli International Journal of Molecular Sciences, 2020, 21, 5533 Doi : 10.3390/ijms21155533 Abstract In this study, we investigated the effects of exposition to IC50 dose for 24 h of a new synthetic cannabinoid (CB83) and of phytocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on HT-29 colorectal carcinoma cells. Cell viability and proliferative activity evaluated using the MTT, lactate dehydrogenase (LDH), and CyQUANT assays showed that cell viability was significantly affected when CB83, THC, and CBD [...]
Lire la suiteCannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer Uchini S. Kosgodage, Rhys Mould, Aine B. Henley, Alistair V. Nunn, Geoffrey W. Guy, E. L. Thomas, Jameel M. Inal, Jimmy D. Bell and Sigrun Lange Frontiers in Pharmacology, 2018, Volume 9, Article 889 doi : 10.3389/fphar.2018.00889 Exosomes and microvesicles (EMV) are lipid bilayer-enclosed structures, released by cells and involved in intercellular communication through transfer of proteins and genetic material. EMV release is also associated with various pathologies, including cancer, where increased EMV release is amongst other associated with chemo-resistance and active transfer of pro-oncogenic factors. Recent studies show that [...]
Lire la suiteThe Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer Oliviero Marinelli, Maria Beatrice Morelli, Daniela Annibali, Cristina Aguzzi, Laura Zeppa, Sandra Tuyaerts, Consuelo Amantini, Frédéric Amant, Benedetta Ferretti, Federica Maggi, Giorgio Santoni, Massimo Nabissi International Journal of Molecular Sciences, 2020, 21, 5409 doi : 10.3390/ijms21155409 Abstract : Several studies support, both in vitro and in vivo, the anti-cancer effects of cannabidiol (CBD), a transient receptor potential vanilloid 2 (TRPV2) ligand. TRPV2, often dysregulated in tumors, is associated with altered cell proliferation and aggressiveness. Endometrial cancer (EC) is historically divided in type I endometrioid EC and type II non-endometrioid EC, associated with [...]
Lire la suiteMedicinal use of cannabis based products and cannabinoids Tom P. Freeman, Chandni Hindocha, Sebastian F. Green, Michael A. P. Bloomfield British Medical Journal, 2019, 365, l1141 doi : 10.1136/bmj.l1141 What you need to know • Cannabis based products for medicinal use contain cannabinoids derived from the cannabis plant, including Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of THC and CBD. Synthetic cannabinoids for medicinal use typically mimic the effects of specific cannabinoids such as THC • THC is the constituent of cannabis that causes the “high,” whereas CBD is not intoxicating at typical doses. THC and CBD have contrasting mechanisms of action and therapeutic indications; THC [...]
Lire la suite5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats Leonardo B.M. Resstel, Rodrigo F. Tavares, Sabrina F.S. Lisboa, Sâmia R.L. Joca, Fernando M.A. Corrêa and Francisco S. Guimarães British Journal of Pharmacology, 2009, 156, 181–188; doi : 10.1111/j.1476-5381.2008.00046.x Background and purpose : Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa which induces anxiolytic- and antipsychotic-like effects in rodents. These effects could be mediated by facilitation of the endocannabinoid system or by the activation of 5-HT1A receptors. As either of these mechanisms could promote adaptation to inescapable stress, the aim of the present work [...]
Lire la suite